CXCL2

Across TCGA pan-cancer cohorts, CXCL2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CXCL2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CXCL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CXCL2 expression acts as an unfavorable survival marker.

HNSC and LUSC are the cancer types where CXCL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.122	0.710	.001	27	view →
LUSC	OS	Median	All	0.172	0.776	.002	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CXCL2–HNSC (DFS)

Open the HNSC breakdown →